View ValuationHLB Genex 将来の成長Future 基準チェック /06現在、 HLB Genexの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Chemicals 収益成長63.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩3,175, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total loss to shareholders of 36% over the past three years.お知らせ • Mar 17HLB Genex, Inc., Annual General Meeting, Mar 30, 2026HLB Genex, Inc., Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 65, techno3-ro, yuseong-gu, daejeon South Korea分析記事 • Feb 02These 4 Measures Indicate That HLB Genex (KOSDAQ:187420) Is Using Debt ExtensivelySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...お知らせ • May 22HLB Genex, Inc. (KOSDAQ:A187420) agreed to acquire an additional 16.41% stake in GF Fermentech Co., Ltd. from Nautic Glow Holdings Co., Ltd. for KRW 8.2 billion.HLB Genex, Inc. (KOSDAQ:A187420) agreed to acquire an additional 16.41% stake in GF Fermentech Co., Ltd. from Nautic Glow Holdings Co., Ltd. for KRW 8.2 billion on May 21, 2025. A cash consideration of KRW 8.17 billion will be paid by HLB Genex, Inc. for 1,078,841 shares. Upon completion, HLB Genex, Inc. will own 57.83% stake in GF Fermentech Co., Ltd. For the period ending December 31, 2024, GF Fermentech Co., Ltd. reported total revenue of KRW 19.03 billion and net income of KRW 4.05 billion. As of December 31, 2024, GF Fermentech Co., Ltd. reported total debt of KRW 18.27 billion, total assets of KRW 40.35 billion and total common equity of KRW 22.08 billion. The expected completion of the transaction is May 26, 2025.New Risk • Mar 30New major risk - Revenue and earnings growthEarnings have declined by 0.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (₩103.4b market cap, or US$70.3m).New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.2x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (₩98.2b market cap, or US$67.2m).お知らせ • Mar 14HLB Genex, Inc., Annual General Meeting, Mar 28, 2025HLB Genex, Inc., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 75, techno1-ro, yuseong-gu, daejeon South Koreaお知らせ • Dec 13GenoFocus, Inc. announced that it has received KRW 69.999981686 billion in funding from a group of investorsOn December 12, 2024 GenoFocus, Inc. closed the transaction.お知らせ • Oct 30GenoFocus, Inc. announced that it expects to receive KRW 55 billion in fundingGenoFocus, Inc. announced a private placement to issue Series 5 Bearer unsecured private placement convertible bonds for a gross proceeds of KRW 55,000,000,000 on October 28, 2024. The bonds a coupon rate of 1% and yield to maturity of 2%. The bonds will mature on December 12, 2027. The bonds will be 100% converted into 17,851,346 common shares at a fixed conversion price of KRW 3,081 per share. The conversion period is from December 12, 2025 to November 12, 2027. The payment date of the transaction is December 12, 2024. The transaction has been approved by the board of directors of the company. The transaction includes participation from Nomad No. 5 Fund for KRW 42,500,000,000, Armart New Technology Fund No. 304 for KRW 9,000,000,000, Lim Jihyun for KRW 3,000,000,000 and The Global Asset Management, Inc. for KRW 500,000,000.分析記事 • Oct 29There's Reason For Concern Over GenoFocus, Inc.'s (KOSDAQ:187420) Massive 30% Price JumpGenoFocus, Inc. ( KOSDAQ:187420 ) shares have had a really impressive month, gaining 30% after a shaky period...お知らせ • Oct 04Nautic Glow Holdings Co., Ltd. agreed to acquire 41.41% stake in GF Fermentech Co., Ltd. from GenoFocus, Inc. (KOSDAQ:A187420) for KRW 19.2 billion.Nautic Glow Holdings Co., Ltd. agreed to acquire 41.41% stake in GF Fermentech Co., Ltd. from GenoFocus, Inc. (KOSDAQ:A187420) for KRW 19.2 billion on September 30, 2024. For the period ending December 31, 2023, GF Fermentech Co., Ltd. reported total revenue of KRW 13.88 billion and net income of KRW 10.13 billion, total debt of KRW 34.35 billion, total assets of KRW 52.41 billion and total common equity of KRW 18.06 billion. The expected completion of the transaction is October 4, 2024.分析記事 • Aug 05GenoFocus (KOSDAQ:187420) Is Carrying A Fair Bit Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Risk • Aug 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (4.4% increase in shares outstanding). Market cap is less than US$100m (₩81.3b market cap, or US$60.0m).分析記事 • Apr 13Is GenoFocus (KOSDAQ:187420) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Mar 21Full year 2020 earnings released: ₩551 loss per share (vs ₩267 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: ₩18.8b (up 26% from FY 2019). Net loss: ₩12.2b (loss widened 112% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 90% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Feb 24New 90-day low: ₩7,700The company is down 20% from its price of ₩9,630 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.分析記事 • Feb 16Can You Imagine How GenoFocus' (KOSDAQ:187420) Shareholders Feel About The 55% Share Price Increase?It hasn't been the best quarter for GenoFocus, Inc. ( KOSDAQ:187420 ) shareholders, since the share price has fallen...Is New 90 Day High Low • Jan 18New 90-day low: ₩8,800The company is down 37% from its price of ₩14,000 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 39% over the same period.分析記事 • Dec 22Is GenoFocus (KOSDAQ:187420) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Sep 23New 90-day high: ₩16,900The company is up 186% from its price of ₩5,900 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 31% over the same period.お知らせ • Aug 30GenoFocus, Inc. announced that it has received KRW 10 billion in fundingOn August 24, 2020, GenoFocus, Inc. (KOSDAQ:A187420) closed the transaction.お知らせ • Aug 22GenoFocus, Inc. announced that it expects to receive KRW 10 billion in fundingGenoFocus, Inc. (KOSDAQ:A187420) announced a private placement of series 3 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 10,000,000,000 on August 21, 2020. The transaction will include participation from K2 Expedio Fund. The bonds carry a Surface interest rate 0% and interest rate to maturity of 3%. The bonds will mature on August 24, 2025. The bonds can be 100% converted into 1,470,804 common shares for 6.65% stake of the company at a fixed conversion price of KRW 6,799 per share. The conversion period is from August 24, 2021 to July 24, 2025. . The transaction is expected to close by August 24, 2020. The transaction has been approved by the board of directors of the company. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、HLB Genex は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A187420 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202543,37022,5912,4273,504N/A9/30/202540,950-3,2762,5203,630N/A6/30/202539,914-972,0402,708N/A3/31/202539,009-18,576-16737N/A12/31/202435,430-18,8282,1712,870N/A9/30/202434,8341,0451,2411,805N/A6/30/202432,197-2,856-2,222-1,133N/A3/31/202428,048-1,444-5,571-4,360N/A12/31/202327,008-2,950-6,148-4,815N/A9/30/202325,340-15,879-8,252-6,413N/A6/30/202325,467-13,668-6,384-4,390N/A3/31/202327,827-13,706-6,140-3,232N/A12/31/202227,802-12,968-9,031-4,711N/A9/30/202227,274-8,837-11,137-3,940N/A6/30/202227,140-8,641-11,580-2,974N/A3/31/202226,427-8,222-12,247-3,383N/A12/31/202125,874-6,817-11,420-2,390N/A9/30/202122,921-10,312-13,914-3,833N/A6/30/202120,533-10,298-14,987-4,716N/A3/31/202119,258-13,035-19,524-3,159N/A12/31/202018,769-12,217-18,064-2,452N/A9/30/202018,853-5,142-14,184-348N/A6/30/202017,807-5,729-12,923-490N/A3/31/202016,287-5,907-9,127-633N/A12/31/201914,942-5,759-10,559-167N/A9/30/201912,878-5,952N/A1,268N/A6/30/201913,169-3,427N/A1,347N/A3/31/201912,388-3,020N/A1,406N/A12/31/201811,518-2,323N/A1,564N/A9/30/201811,592-43N/A1,088N/A6/30/201811,138433N/A2,493N/A3/31/201811,6851,457N/A1,782N/A12/31/201711,5061,411N/A1,364N/A9/30/201710,9222,044N/A1,525N/A6/30/20179,8952,214N/A330N/A3/31/20178,0542,123N/A1,188N/A12/31/20167,0291,615N/A516N/A9/30/20166,562874N/A880N/A6/30/20166,4611,243N/A1,124N/A3/31/20166,6541,187N/A2,081N/A12/31/20156,6401,211N/A2,854N/A9/30/20158,4103,192N/A1,370N/A6/30/20157,7962,569N/A923N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A187420の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A187420の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A187420の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A187420の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A187420の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A187420の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 09:56終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋HLB Genex, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩3,175, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 16x in the Chemicals industry in South Korea. Total loss to shareholders of 36% over the past three years.
お知らせ • Mar 17HLB Genex, Inc., Annual General Meeting, Mar 30, 2026HLB Genex, Inc., Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 65, techno3-ro, yuseong-gu, daejeon South Korea
分析記事 • Feb 02These 4 Measures Indicate That HLB Genex (KOSDAQ:187420) Is Using Debt ExtensivelySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
お知らせ • May 22HLB Genex, Inc. (KOSDAQ:A187420) agreed to acquire an additional 16.41% stake in GF Fermentech Co., Ltd. from Nautic Glow Holdings Co., Ltd. for KRW 8.2 billion.HLB Genex, Inc. (KOSDAQ:A187420) agreed to acquire an additional 16.41% stake in GF Fermentech Co., Ltd. from Nautic Glow Holdings Co., Ltd. for KRW 8.2 billion on May 21, 2025. A cash consideration of KRW 8.17 billion will be paid by HLB Genex, Inc. for 1,078,841 shares. Upon completion, HLB Genex, Inc. will own 57.83% stake in GF Fermentech Co., Ltd. For the period ending December 31, 2024, GF Fermentech Co., Ltd. reported total revenue of KRW 19.03 billion and net income of KRW 4.05 billion. As of December 31, 2024, GF Fermentech Co., Ltd. reported total debt of KRW 18.27 billion, total assets of KRW 40.35 billion and total common equity of KRW 22.08 billion. The expected completion of the transaction is May 26, 2025.
New Risk • Mar 30New major risk - Revenue and earnings growthEarnings have declined by 0.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (₩103.4b market cap, or US$70.3m).
New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.2x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (₩98.2b market cap, or US$67.2m).
お知らせ • Mar 14HLB Genex, Inc., Annual General Meeting, Mar 28, 2025HLB Genex, Inc., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 75, techno1-ro, yuseong-gu, daejeon South Korea
お知らせ • Dec 13GenoFocus, Inc. announced that it has received KRW 69.999981686 billion in funding from a group of investorsOn December 12, 2024 GenoFocus, Inc. closed the transaction.
お知らせ • Oct 30GenoFocus, Inc. announced that it expects to receive KRW 55 billion in fundingGenoFocus, Inc. announced a private placement to issue Series 5 Bearer unsecured private placement convertible bonds for a gross proceeds of KRW 55,000,000,000 on October 28, 2024. The bonds a coupon rate of 1% and yield to maturity of 2%. The bonds will mature on December 12, 2027. The bonds will be 100% converted into 17,851,346 common shares at a fixed conversion price of KRW 3,081 per share. The conversion period is from December 12, 2025 to November 12, 2027. The payment date of the transaction is December 12, 2024. The transaction has been approved by the board of directors of the company. The transaction includes participation from Nomad No. 5 Fund for KRW 42,500,000,000, Armart New Technology Fund No. 304 for KRW 9,000,000,000, Lim Jihyun for KRW 3,000,000,000 and The Global Asset Management, Inc. for KRW 500,000,000.
分析記事 • Oct 29There's Reason For Concern Over GenoFocus, Inc.'s (KOSDAQ:187420) Massive 30% Price JumpGenoFocus, Inc. ( KOSDAQ:187420 ) shares have had a really impressive month, gaining 30% after a shaky period...
お知らせ • Oct 04Nautic Glow Holdings Co., Ltd. agreed to acquire 41.41% stake in GF Fermentech Co., Ltd. from GenoFocus, Inc. (KOSDAQ:A187420) for KRW 19.2 billion.Nautic Glow Holdings Co., Ltd. agreed to acquire 41.41% stake in GF Fermentech Co., Ltd. from GenoFocus, Inc. (KOSDAQ:A187420) for KRW 19.2 billion on September 30, 2024. For the period ending December 31, 2023, GF Fermentech Co., Ltd. reported total revenue of KRW 13.88 billion and net income of KRW 10.13 billion, total debt of KRW 34.35 billion, total assets of KRW 52.41 billion and total common equity of KRW 18.06 billion. The expected completion of the transaction is October 4, 2024.
分析記事 • Aug 05GenoFocus (KOSDAQ:187420) Is Carrying A Fair Bit Of DebtDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • Aug 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 4.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (4.4% increase in shares outstanding). Market cap is less than US$100m (₩81.3b market cap, or US$60.0m).
分析記事 • Apr 13Is GenoFocus (KOSDAQ:187420) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Mar 21Full year 2020 earnings released: ₩551 loss per share (vs ₩267 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: ₩18.8b (up 26% from FY 2019). Net loss: ₩12.2b (loss widened 112% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 90% per year but the company’s share price has only fallen by 20% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Feb 24New 90-day low: ₩7,700The company is down 20% from its price of ₩9,630 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 16% over the same period.
分析記事 • Feb 16Can You Imagine How GenoFocus' (KOSDAQ:187420) Shareholders Feel About The 55% Share Price Increase?It hasn't been the best quarter for GenoFocus, Inc. ( KOSDAQ:187420 ) shareholders, since the share price has fallen...
Is New 90 Day High Low • Jan 18New 90-day low: ₩8,800The company is down 37% from its price of ₩14,000 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 39% over the same period.
分析記事 • Dec 22Is GenoFocus (KOSDAQ:187420) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Sep 23New 90-day high: ₩16,900The company is up 186% from its price of ₩5,900 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 31% over the same period.
お知らせ • Aug 30GenoFocus, Inc. announced that it has received KRW 10 billion in fundingOn August 24, 2020, GenoFocus, Inc. (KOSDAQ:A187420) closed the transaction.
お知らせ • Aug 22GenoFocus, Inc. announced that it expects to receive KRW 10 billion in fundingGenoFocus, Inc. (KOSDAQ:A187420) announced a private placement of series 3 unregistered nonguaranteed private convertible bond for gross proceeds of KRW 10,000,000,000 on August 21, 2020. The transaction will include participation from K2 Expedio Fund. The bonds carry a Surface interest rate 0% and interest rate to maturity of 3%. The bonds will mature on August 24, 2025. The bonds can be 100% converted into 1,470,804 common shares for 6.65% stake of the company at a fixed conversion price of KRW 6,799 per share. The conversion period is from August 24, 2021 to July 24, 2025. . The transaction is expected to close by August 24, 2020. The transaction has been approved by the board of directors of the company.